RT @feliciaTSR: On the 6th day of Christmas🎄our GNOC Cochrane review @LindaMileshkin https://t.co/TY8JWYU6q6
On the 6th day of Christmas🎄our GNOC Cochrane review @LindaMileshkin
On the 6th day of advent …. https://t.co/kCnZiXDCjG Bringing you a run-down of our 2019 reviews & protocols in our Cochrane GNOC evidence advent calendar…… #CGNOCadvent19 @CochraneLibrary @CochraneUK @cochranecollab @feliciaTSR @CochraneBCancer https
RT @Cochrane_GNOCG: No clear benefit in overall survival or tumour response rate. But there is still five ongoing studies investigating the…
Cochrane #systematicreview PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer https://t.co/3j33bRG362 In a recurrent disease setting, mTOR inhibitors may result in improved progression‐free survival, but no clear benefit in overall survi
Cochrane Review: PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer https://t.co/r2BD8SQbuE #cancer
RT @Cochrane_GNOCG: No clear benefit in overall survival or tumour response rate. But there is still five ongoing studies investigating the…
RT @Cochrane_GNOCG: No clear benefit in overall survival or tumour response rate. But there is still five ongoing studies investigating the…
No clear benefit in overall survival or tumour response rate. But there is still five ongoing studies investigating the role of PI3K/AKT/mTOR inhibitors in advanced or recurrent endometrial cancer https://t.co/kCnZiXDCjG @CochraneLibrary @CochraneUK